🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

265 results for “LG” Clear

  1. Study of diclofenac skin reservoir formation and emptying after Voltaren Emulgel 2.32% application in healthy participants

    HALEON AUSTRALIA PTY LTD

    For the local, symptomatic treatment of pain in acute bruises, strains, or sprains due to blunt trauma, e.g., sports and accident injuries

    phase 1 other active

    1 trial

  2. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  3. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  4. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  5. ZG0895 Hydrochloride for Injection

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  6. filgrastim

    Ultragenyx UK Limited

    Fanconi's Anemia

    phase 1 small molecule active

    1 trial

  7. lipegfilgrastim

    Teva Pharma GmbH

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  8. pomalidomide

    Celgene Europe Limited

    Multiple Myeloma in Relapse

    phase 1 small molecule completed

    1 trial

  9. Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]

    AVENUE THERAPEUTICS, INC.

    Acne Vulgaris

    approved small molecule completed

    1 trial

  10. Algorithm Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    approved small molecule completed

    1 trial

  11. Buccal Buprenorphine 300 mcg

    BRIGHT MINDS BIOSCIENCES INC.

    Analgesia

    approved small molecule active

    1 trial

  12. Bupivacaine HCl

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    1 trial

  13. Bupivacaine Hydrochloride

    Heron Therapeutics

    Analgesia

    approved small molecule active

    1 trial

  14. Bupivacaine Liposome Injection

    Jian Li

    Local Analgesia Via Infiltration

    approved small molecule active

    1 trial

  15. Bupivacaine liposome injectable suspension

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    1 trial

  16. Conducted AF-Response Algorithm (CAFR) On

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    approved other terminated

    1 trial

  17. Continuos epidural infusion

    Hospital Authority, Hong Kong

    Analgesia, Epidural

    approved other active

    1 trial

  18. Erythromycin 4% topical gel formulation

    BRIGHT MINDS BIOSCIENCES INC.

    Acne Vulgaris

    approved small molecule active

    1 trial

  19. Exparel

    Pacira Ireland Limited

    Analgesia, Postoperative

    approved small molecule completed

    1 trial

  20. Filgotinib

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    approved small molecule active

    8 trials

  21. HTX-011

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    6 trials

  22. Isotretinoin

    VYNE Therapeutics

    Acne Vulgaris

    approved small molecule completed

    1 trial

  23. KENACORT 40 mg/ml sospensione iniettabile, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio, Lidocaína B. Braun 20 mg/ml solución inyectable, BUPIVACAÍNA PHYSAN 0,25% SOLUCIÓN INYECTABLE

    The George Institute

    TRAPEZIUS MYOFASCIAL SYNDROME IN FIBROMYALGIA PATIENTS

    approved small molecule active

    1 trial

  24. Microcrystalline cellulose, GABAPENTINE BIOGARAN 300 mg, gélule

    The George Institute

    lumbosacral radiculalgia

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources